Drug
Lintuzumab
Lintuzumab: highest development phase Phase 1, developed by Seagen. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Seagen
Trials
| Drug | Phase | Indication |
|---|---|---|
| lintuzumab NCT00502112 | Phase 1 | Myelodysplastic Syndrome (MDS) |
| lintuzumab NCT00283114 | Phase 1 | Acute Myeloid Leukemia |
Latest
No recent events.
Follow Lintuzumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.